JP2025511929A - 長時間作用型顆粒球マクロファージコロニー刺激因子 - Google Patents

長時間作用型顆粒球マクロファージコロニー刺激因子 Download PDF

Info

Publication number
JP2025511929A
JP2025511929A JP2024559555A JP2024559555A JP2025511929A JP 2025511929 A JP2025511929 A JP 2025511929A JP 2024559555 A JP2024559555 A JP 2024559555A JP 2024559555 A JP2024559555 A JP 2024559555A JP 2025511929 A JP2025511929 A JP 2025511929A
Authority
JP
Japan
Prior art keywords
composition
patient
csf
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511929A5 (https=
Inventor
フェルドハウス、マイケル
ミャオ、シアオニウ
ワン、チャオ
ロウ、イー
ツォウ、ユエフォン
Original Assignee
パートナー セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パートナー セラピューティクス インコーポレイテッド filed Critical パートナー セラピューティクス インコーポレイテッド
Publication of JP2025511929A publication Critical patent/JP2025511929A/ja
Publication of JP2025511929A5 publication Critical patent/JP2025511929A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024559555A 2022-04-08 2023-03-28 長時間作用型顆粒球マクロファージコロニー刺激因子 Pending JP2025511929A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263329039P 2022-04-08 2022-04-08
US63/329,039 2022-04-08
PCT/US2023/065047 WO2023196747A1 (en) 2022-04-08 2023-03-28 Long-acting granulocyte macrophage-colony stimulating factor

Publications (2)

Publication Number Publication Date
JP2025511929A true JP2025511929A (ja) 2025-04-16
JP2025511929A5 JP2025511929A5 (https=) 2026-04-06

Family

ID=88243563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559555A Pending JP2025511929A (ja) 2022-04-08 2023-03-28 長時間作用型顆粒球マクロファージコロニー刺激因子

Country Status (9)

Country Link
US (1) US20250230210A1 (https=)
EP (1) EP4504262A4 (https=)
JP (1) JP2025511929A (https=)
KR (1) KR20250004698A (https=)
CN (1) CN119136831A (https=)
AU (1) AU2023248440A1 (https=)
CA (1) CA3247715A1 (https=)
TW (1) TW202342089A (https=)
WO (1) WO2023196747A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025247334A1 (en) * 2024-05-30 2025-12-04 Biosion Inc. Recombinant fusion protein targeting siglec15 and gm-csfr
CN118909139A (zh) * 2024-07-24 2024-11-08 广东壹加再生医学研究院有限公司 一种活化树突状细胞的分子、方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
HUE070957T2 (hu) * 2017-02-16 2025-07-28 Sonnet Biotherapeutics Inc Albuminkötõ domén fúziós fehérjék
CA3070253A1 (en) * 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
JP2023514972A (ja) * 2020-02-12 2023-04-12 ザ スクリプス リサーチ インスティテュート 長時間作用型ｇｍ－ｃｓｆおよび使用方法

Also Published As

Publication number Publication date
EP4504262A1 (en) 2025-02-12
CA3247715A1 (en) 2023-10-12
AU2023248440A1 (en) 2024-10-17
KR20250004698A (ko) 2025-01-08
WO2023196747A1 (en) 2023-10-12
EP4504262A4 (en) 2026-04-15
US20250230210A1 (en) 2025-07-17
CN119136831A (zh) 2024-12-13
TW202342089A (zh) 2023-11-01

Similar Documents

Publication Publication Date Title
JP2026048634A (ja) 獣医学用ｉｇｇ ｆｃ変異体
CN107074928B (zh) 新型猫促红细胞生成素受体激动剂
TWI598361B (zh) Ｃｘ３ｃｒ１－結合多肽
RU2651776C2 (ru) Биспецифические антитела против cd3*cd19
US10695404B2 (en) Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
CA3053906A1 (en) Albumin binding domain fusion proteins
KR20190140943A (ko) 항-cd33 항체 제제
KR20170094341A (ko) 인터류킨 15 단백질 복합체 및 그의 용도
EP3019533A2 (en) Coiled coil immunoglobulin fusion proteins and compositions thereof
EP2697257A2 (en) Fc fusion proteins comprising novel linkers or arrangements
CA2943445A1 (en) Binding members to tnf alpha
JP2025511929A (ja) 長時間作用型顆粒球マクロファージコロニー刺激因子
CA3195315A1 (en) Compositions and methods for selective depletion of target molecules
US20220372495A1 (en) Fusion polypeptides
KR102917499B1 (ko) 백혈병 억제 인자 활성을 억제하기 위한 가용성 폴리펩타이드 및 이의 사용 방법
JP2023547883A (ja) 顆粒球マクロファージコロニー刺激因子変異体
JP2023553117A (ja) 顆粒球マクロファージコロニー刺激因子の製造
CN116507355A (zh) 粒细胞巨噬细胞集落刺激因子突变体
JP2024546726A (ja) 抗体－サイトカイン融合タンパク質及びその用途
HK40066087A (zh) Cxcr4结合分子
HK40099163A (zh) Ph依赖性突变型白细胞介素-2多肽
KR20170027795A (ko) 항-사이토카인 항체의 동정을 위한 인간-유래 항-인간 il-20 항체 및 검정
HK1233661B (en) Binding members to tnf alpha

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260327